Earnshaw S, McDade C, Bryan A, Ines M, Micallef C, Sung A, Enoch D. Real-world financial and clinical impact of diagnostic-driven and empirical-treatment strategies in high-risk immunocompromised patients with suspected aspergillus infection in the United Kingdom. Microbiol Spectr. 2022 Jun 29;10(3):e0042522. doi: 10.1128/spectrum.00425-22
Patterson B, Curran D, Buck P, Varghese L, Oorschot D, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of candidate adjuvanted subunit vaccine for vaccinating U.S. adults not previously vaccinated against herpes zoster. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 25, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S20.
Buck PO, Curran D, Patterson BJ, Varghese L, van Oorschot D, Carrico J, Hicks K, Lee BY, Yawn BP. Cost-effectiveness of adjuvanted recombinant zoster vaccine (RZV) for vaccinating US adults not previously vaccinated against herpes zoster. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 25, 2018. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S20.
Talbird SE, Graham JB, Mauskopf JA, Masseria C, Krishnarajah G. Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases. J Manag Care Pharm. 2015 Jan;21(1):88-99.